CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver.

  • Authors:
    • P Mitra
    • K Shibuta
    • J Mathai
    • K Shimoda
    • B F Banner
    • M Mori
    • G F Barnard
  • View Affiliations

  • Published online on: May 1, 1999     https://doi.org/10.3892/ijo.14.5.917
  • Pages: 917-942
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have recently demonstrated by Northern blot and RT-PCR that the mRNA expression of the alpha-chemokine hIRH/SDF-1alpha is reduced in hepatocellular carcinoma (HCC), several digestive tract cancers and premalignant colon adenomas, and that its receptor CXCR4 mRNA expression is reduced in HCC. Here we investigate the expression of CXCR4 mRNA expression in several digestive tract cancers and hepatitis C viral (HCV) infected liver, a premalignant condition. There was no difference in the CXCR4 mRNA expression in colon, esophageal or gastric cancers compared to non-cancerous tissues. This is significantly different from the reduced expression we have seen with hepatocellular carcinoma (p<0.05). To better refine regional tumor or hepatic cytokine mRNA analysis within a biopsy sample we describe a micro-isolation technique for RNA extraction from portal and triad areas of liver biopsies or other small malignant or non-malignant biopsy samples suitable for use in RT-PCR and differential display reactions. In HCV liver biopsies, the expression of hIRH and its receptor CXCR4 mRNA, corrected for G3PDH, was not significantly different from that of control non-HCV (steatosis) biopsies. CXCR4 is expressed on leukocytes and its expression was predicted to correlate with hepatic inflammation. CXCR4 receptor mRNA expression did correlate significantly with that of its ligand hIRH/SDF-1alpha (p=0.001), and with the severity of fibrosis (p<0.05), but not with portal inflammation (p<0.10), piecemeal necrosis (p<0.10), lobular inflammation (p>0.10), the presence of lymphoid aggregates (p>0.10), or the total histological activity index (p=0.07). There was no difference in expression of hIRH or CXCR4 between responders and non-responders to interferon (IFN) treatment, while as a control, the responder group of patients did show a higher expression of IFNalpha receptor than the non-responder group (p=0.05).

Related Articles

Journal Cover

May 1999
Volume 14 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mitra, P., Shibuta, K., Mathai, J., Shimoda, K., Banner, B., Mori, M., & Barnard, G. (1999). CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver.. International Journal of Oncology, 14, 917-942. https://doi.org/10.3892/ijo.14.5.917
MLA
Mitra, P., Shibuta, K., Mathai, J., Shimoda, K., Banner, B., Mori, M., Barnard, G."CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver.". International Journal of Oncology 14.5 (1999): 917-942.
Chicago
Mitra, P., Shibuta, K., Mathai, J., Shimoda, K., Banner, B., Mori, M., Barnard, G."CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver.". International Journal of Oncology 14, no. 5 (1999): 917-942. https://doi.org/10.3892/ijo.14.5.917